iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

The European Commission has approved the ophthalmology biosimilar Yesafili from Biocon Biologics

21 Sep 2023 , 01:33 PM

Yesafili, a biosimilar to Aflibercept, has been given marketing authorization in the European Union (EU) by the European Commission (EC), according to a news release issued by Biocon Biologics on September 20.

After the European Medicines Agency’s favourable assessment and recommendation for Yesafili’s clearance in July, the EC made its decision.

Yesafili, an ophthalmology product, is used to treat neovascular (wet AMD), age-related macular degeneration, visual impairment brought on by diabetic macular oedema (DME), central or branch retinal vein occlusion, and myopic choroidal neovascularization (myopic CNV), as well as visual impairment brought on by macular oedema secondary to retinal vein occlusion. It closely resembles the benchmark product, Eylea (aflibercept). According to data, Yesafili and Eylea are comparable in terms of quality, safety, and effectiveness.

All EU member states as well as Iceland, Liechtenstein, and Norway that are members of the European Economic Area (EEA) are eligible to use the centralised marketing authorization that the EC has issued.

Nearly half of Biocon Limited’s consolidated revenue of Rs 115,501 million, up 38% from the previous fiscal year, came from the biosimilar sector, which had a growth of 61% in FY 23.

According to IQVIA, Aflibercept had EU brand sales of almost $1.8 billion for the 12 months ending December 31, 2022.

For feedback and suggestions, write to us at editorial@iifl.com

Biocon Biologics - Transforming Healthcare. Transforming Lives.

Related Tags

  • Biocon Biologics
  • European Commission
  • Yesafili
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.